Ligand Pharmaceuticals (LGND) to acquire XOMA Royalty (XOMA) for $739m as biotech royalty consolidation accelerates

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has agreed to acquire XOMA Royalty Corporation (NASDAQ: XOMA) for $39.00 per share in cash, valuing the smaller biotech royalty aggregator at roughly $739 million in equity, with XOMA Royalty stockholders also receiving one non-transferable contingent value right per share tied to ongoing litigation against Janssen Biotech over the commercialisation of TREMFYA. The cash component represents an approximately 14 percent premium to XOMA Royalty’s 30-day volume weighted average price as of April 24, 2026, but only about a 3 percent premium to the prior closing print, signalling that public markets had already begun pricing in deal speculation. Ligand Pharmaceuticals expects the transaction to close in the third quarter of 2026, to be immediately accretive to adjusted earnings per share, and to add roughly $1.50 to adjusted EPS in 2027. With LGND trading at $231.73 as of April 17, 2026, near its 52-week high of $234.76 and up more than 22 percent year to date, Ligand Pharmaceuticals is consolidating from a position of strength rather than necessity.

What does the Ligand Pharmaceuticals acquisition of XOMA Royalty signal about consolidation in the biotech royalty aggregator market?

The deal collapses two of the most visible publicly traded biotech royalty aggregators into a single platform. Ligand Pharmaceuticals already manages economic interests in more than 100 development and commercial stage assets. The XOMA Royalty portfolio adds over 120 commercial, clinical, and preclinical programmes, taking the combined royalty book past 200 assets and roughly doubling the bench of Phase 2 and Phase 3 programmes in one stroke. For a sector built on the premise that royalty stacking smooths revenue volatility, the combination materially shifts the diversification profile in Ligand Pharmaceuticals’ favour.

The strategic logic also sharpens the competitive picture. Royalty aggregation as a model sits between traditional pharma deal-making and specialty financing, and the addressable universe of attractive late-stage royalties is finite. By absorbing XOMA Royalty, Ligand Pharmaceuticals removes a direct competitor from the bidding table for future royalty acquisitions, particularly in the smaller and mid-sized transaction tier where XOMA Royalty had been most active. The signal to private royalty buyers, sovereign capital pools, and structured finance desks targeting the same asset class is unambiguous, with scale increasingly a prerequisite for deal access and pricing power.

The risk to that thesis is integration cadence. XOMA Royalty under Owen Hughes spent the past three years aggressively scaling, including the acquisitions of Mural Oncology and Generation Bio, and has built a portfolio whose monitoring, milestone tracking, and partner relationships now need to plug into Ligand Pharmaceuticals’ operating model without value leakage. Royalty aggregation looks passive on paper but is in practice an information-intensive business, and execution slippage during the integration window would erode the very synergies that justify the premium.

Why is the contingent value right tied to the Johnson & Johnson TREMFYA litigation the most important number nobody is publishing?

The cleanest read of the transaction structure is that Ligand Pharmaceuticals is buying the operating royalty portfolio while letting XOMA Royalty stockholders retain the upside on a single, hard-to-value lawsuit. The contingent value right entitles holders to a portion of 75 percent of any net proceeds recovered from XOMA Royalty’s dispute with Janssen Biotech, now part of Johnson & Johnson Innovative Medicine, over the commercialisation of TREMFYA, the blockbuster psoriasis and inflammatory bowel disease antibody.

The scale of that lawsuit is what changes the calculus. Johnson & Johnson has reported cumulative TREMFYA net revenues of roughly $19.7 billion since 2017, and XOMA Royalty’s claims of breach of contract and unjust enrichment trace back to a 2003 era agreement with MorphoSys involving phage display and HuCAL technologies allegedly used to generate the antibody. Outgoing XOMA Royalty leadership has publicly described high confidence in the breach claim, while emphasising that litigation outcomes and timing remain uncertain. Even a modest royalty rate applied to a fraction of those cumulative sales would produce a CVR payout meaningfully larger than the cash consideration, which helps explain why XOMA Royalty shares traded at $41.45 on the announcement, roughly 6 percent above the $39.00 cash price. The market is openly assigning tangible expected value to the litigation outcome.

For Ligand Pharmaceuticals, ring-fencing the Janssen Biotech case via the CVR is a clean piece of financial engineering. It removes binary legal risk from the acquired entity’s go-forward valuation, makes the deal cleaner for credit committees underwriting the financing, and avoids forcing Ligand Pharmaceuticals to mark a contested receivable on its own balance sheet. The trade-off is that any eventual large recovery accrues primarily to legacy XOMA Royalty stockholders rather than to Ligand Pharmaceuticals.

How does the Ligand Pharmaceuticals revised 2026 financial guidance reframe the investment narrative for LGND stockholders?

The numerical update is unusually generous for a deal still months from closing. Ligand Pharmaceuticals raised 2026 revenue guidance to a range of $270 million to $310 million, up from $245 million to $285 million, with royalty revenue now expected to land between $225 million and $250 million, compared with $200 million to $225 million previously. Captisol sales guidance of $35 million to $40 million and contract revenue guidance of $10 million to $20 million were left unchanged, isolating the entire upgrade to royalty performance and the inbound XOMA Royalty contribution.

Adjusted earnings per diluted share guidance moved to $8.50 to $9.50, from $8.00 to $9.00, with the company guiding to additional $1.50 of adjusted EPS accretion in 2027. Stripping out the partial-year contribution and the closing dynamics, the implied annualised earnings power of the combined platform is materially higher than what consensus had been carrying, and the 2027 number anchors a forward growth profile that is harder for sceptics to argue against without challenging the integration assumptions directly.

The capital structure cost is real but contained. The cash consideration will be funded from existing cash and borrowings under Ligand Pharmaceuticals’ credit facility, increasing near-term leverage. Investors will want clarity on the marginal cost of debt, the covenant headroom under the existing facility, and how aggressively management intends to deleverage from the cash flows now expected to compound from the larger royalty base. With LGND trading near 52-week highs and analysts at H.C. Wainwright and Bank of America already raising price targets earlier in April, the market reaction to the deal will be a useful test of whether the equity story is now pricing in the synergies or simply the headline accretion.

Which assets in the XOMA Royalty portfolio actually move the strategic needle for Ligand Pharmaceuticals?

The acquired royalty book is broader than the headline talking points suggest. The seven marketed products include Roche’s VABYSMO (faricimab-svoa), Day One Pharmaceuticals’ OJEMDA (tovorafenib), and Zevra Therapeutics’ MIPLYFFA (arimoclomol), each of which sits in a distinct therapeutic area. VABYSMO is an established commercial franchise in retinal disease for Roche, OJEMDA addresses paediatric low-grade glioma in oncology, and MIPLYFFA is a rare disease asset for Niemann-Pick disease type C. The diversification across ophthalmology, oncology, and rare disease meaningfully reduces single-therapy concentration risk in Ligand Pharmaceuticals’ commercial royalty mix.

The late-stage clinical bench is arguably more important. The 14 programmes in late-stage development include Takeda’s mezagitamab, alongside externalised Takeda assets such as osavampator, volixibat, and OHB-607. Each of those programmes targets a different commercial endpoint, ranging from immune-mediated diseases to central nervous system indications and neonatal pulmonary applications. For a royalty aggregator, optionality across modality and therapeutic area is the entire investment thesis, because a single delayed approval or label setback at the portfolio level becomes a non-event rather than a revenue cliff.

The sleeper consideration is platform exposure. XOMA Royalty acquired two platform technologies during its recent scaling phase, and platform royalties behave differently from single-asset royalties because they participate in the success of multiple programmes derived from the same technology stack. How Ligand Pharmaceuticals chooses to underwrite, model, and report platform royalty value in its periodic disclosures will influence how analysts frame the combined entity’s growth ceiling.

What execution and regulatory risks could derail or reshape the Ligand Pharmaceuticals XOMA Royalty transaction?

The path to closing looks navigable but is not free of friction. The transaction has been unanimously approved by both boards, and entities affiliated with BVF Partners, which beneficially own approximately 47 percent of XOMA Royalty shares assuming conversion of their Series X Convertible Preferred Stock, have signed voting agreements supporting the deal. Officers and directors of XOMA Royalty have done the same. Combined with the conversion of Series X preferred shares prior to closing and the redemption of Series A and Series B preferred stock, the path through the XOMA Royalty stockholder vote looks structurally protected.

Regulatory review is the bigger variable. While royalty aggregation is not the kind of business model that typically attracts antitrust scrutiny in the way of a horizontal pharma combination, the sheer concentration of late-stage royalty interests in a single publicly traded vehicle could draw attention from competition authorities testing whether royalty financing for biotech innovators meaningfully narrows after the deal. Customary closing conditions and the third quarter 2026 timeline both leave room for deal scope or remedy adjustments, although neither company has flagged competition risk as a primary concern.

The second-order risk is more strategic than legal. Royalty aggregators trade in part on perception of disciplined capital allocation and pricing rigour. Paying a premium that compresses to roughly 3 percent over the prior close, while structuring the litigation upside as a CVR rather than embedded equity, is a defensible piece of dealmaking, but it sets a reference point. Future royalty consolidation transactions, both for Ligand Pharmaceuticals and for competitors, will be benchmarked against this structure, particularly the use of CVRs to ring-fence binary litigation outcomes.

What are the key takeaways from the Ligand Pharmaceuticals acquisition of XOMA Royalty for biotech royalty investors and the broader sector?

• Ligand Pharmaceuticals is acquiring XOMA Royalty for $39.00 per share in cash plus a litigation-linked CVR, valuing the deal at approximately $739 million in equity and consolidating two of the most visible publicly traded biotech royalty aggregators into one platform.
• The combined royalty portfolio crosses 200 assets, with seven marketed products including VABYSMO, OJEMDA, and MIPLYFFA, and 14 late-stage programmes anchored by Takeda assets such as mezagitamab, osavampator, volixibat, and OHB-607.
• The contingent value right tied to XOMA Royalty’s TREMFYA litigation against Janssen Biotech is the most consequential off-balance-sheet feature of the transaction, with cumulative drug sales of roughly $19.7 billion since 2017 framing the potential recovery scale.
• XOMA Royalty shares traded at $41.45 against the $39.00 cash offer, a clear signal that the market is independently pricing tangible expected value into the Janssen Biotech litigation outcome rather than treating the CVR as optionality of last resort.
• Ligand Pharmaceuticals raised 2026 revenue guidance to $270 million to $310 million and adjusted EPS guidance to $8.50 to $9.50, with $1.50 of additional adjusted EPS accretion expected in 2027, reframing the forward earnings trajectory for LGND.
• LGND trades near 52-week highs at roughly $231, having returned more than 22 percent year to date, meaning Ligand Pharmaceuticals is consolidating from financial and equity-market strength rather than under defensive pressure.
• The cash consideration will be funded with existing cash and credit facility borrowings, increasing near-term leverage and shifting investor focus to deleveraging cadence and the marginal cost of debt under the financing.
• Ring-fencing the Janssen Biotech litigation via a non-transferable CVR is a clean piece of financial engineering, removing binary legal risk from the acquired entity while preserving upside for legacy XOMA Royalty stockholders.
• BVF Partners and XOMA Royalty insiders, controlling approximately 47 percent of shares on a converted basis, have signed voting agreements supporting the deal, materially de-risking the stockholder approval pathway.
• Royalty aggregation is consolidating into a scale game, and the Ligand Pharmaceuticals XOMA Royalty transaction sets a template for using CVRs to handle binary litigation outcomes that future biotech royalty deals will be benchmarked against.